The spectrometers will also measure properties including molecularweight, electrical charges and the amount of light absorbed at different wavelengths.
Novartis and Momenta alleged that the lack of information about the molecularweight of the molecules rendered the patents unenforceable, according to a note to investors by Sanford C.